141 results on '"Pei, Jinglan"'
Search Results
2. Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination
3. The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome
4. One-year Analysis of Efficacy and Safety Data from Black/African American and Hispanic/Latino People with Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial (PL5.005)
5. Evolution of atrophied T2 lesion volume in primary-progressive multiple sclerosis: results from the phase 3 ORATORIO study.
6. Evolution of atrophied T2 lesion volume in primary-progressive multiple sclerosis: results from the phase 3 ORATORIO study
7. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations
8. Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
9. Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
10. An Interim Analysis of Efficacy and Safety Data in Black and Hispanic Patients With Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial (S31.006)
11. Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis
12. Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis
13. Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study
14. Hybrid and vaccine‐induced immunity against SAR‐CoV ‐2 in MS patients on different disease‐modifying therapies
15. Demographics and Baseline Disease Characteristics of Black and Hispanic Patients With Multiple Sclerosis in the CHIMES Trial (P4-4.005)
16. Evaluating the Impact of Administration of Ocrelizumab via Home Infusion on Safety and Patient Reported Outcomes (P16-4.005)
17. Humoral and Cellular Responses to SARS-CoV-2 Vaccines in MS Patients on Ocrelizumab and Other Disease-modifying Therapies: A Prospective Study From NYU Multiple Sclerosis Care Center (P1-1.Virtual)
18. Cellular and Humoral Immunity to SARS‐CoV‐2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease‐Modifying Therapies: A Multi‐Ethnic Observational Study
19. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
20. Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies
21. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects
22. Supplement to: Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
23. Evolution of Lesions that Shrink or Disappear into Cerebrospinal Fluid (Atrophied T2 Lesion Volume) in Primary-Progressive Multiple Sclerosis: Results from the Phase III ORATORIO Study (107)
24. Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis
25. Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
26. An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability
27. Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study
28. Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy
29. AB0272 EVALUATION OF CXCL13, SICAM-1, MMP-3 AND S100A8/A9 AS SERUM BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH SUBCUTANEOUS TOCILIZUMAB
30. THU0321 CLINICAL OUTCOMES OF PATIENTS WITH GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA SYMPTOMS TREATED WITH TOCILIZUMAB IN ROUTINE CLINICAL PRACTICE
31. FRI0261 RISK FACTORS FOR TREATMENT FAILURE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB PLUS PREDNISONE VERSUS PREDNISONE ALONE
32. FRI0262 CLINICAL OUTCOMES OF PATIENTS WITH GIANT CELL ARTERITIS WITH POLYMYALGIA SYMPTOMS ONLY VS CRANIAL SYMPTOMS ONLY TREATED WITH TOCILIZUMAB OR PLACEBO IN THE GIACTA TRIAL
33. SAT0248 CLINICAL OUTCOMES OF PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN REAL-WORLD CLINICAL PRACTICE
34. Evaluation of shorter infusion times with ocrelizumab in patients with relapsing-remitting multiple sclerosis (P3.2-034)
35. 274. CLINICAL OUTCOMES OF PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN REAL-WORLD CLINICAL PRACTICE
36. Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial
37. Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy.
38. Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab
39. Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
40. Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis
41. Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials
42. Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With Tocilizumab
43. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis
44. Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis
45. Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry.
46. Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis.
47. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
48. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
49. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects
50. 358. Risk factors for treatment failure in patients with giant cell arteritis treated with tocilizumab plus prednisone versus prednisone alone.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.